Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
Previous HAV vaccination does not reliably protect some patients with HIV

Study findings suggest that previous vaccination against hepatitis A virus infection does not reliably protect some people with HIV.

Published
16 hours ago
From
Healio
England hits WHO 2020 hepatitis C target three years early

Deaths from liver disease related to serious hepatitis C (HCV) fell by more than 16% between 2015 and 2017, according to data published by Public Health England (PHE). As a result, England has hit the World Health Organization’s (WHO’s) target to reduce HCV related mortality by 10% by 2020 three years early.

Published
16 hours ago
From
The Pharmaceutical Journal
Gilead's first big TV push for triple combo Biktarvy showcases HIV diversity

Gilead Sciences wanted to represent the wide range of people living with HIV in its first national TV campaign for Biktarvy. So they chose black, Latino, male, female, gay, bisexual and transgender actors for an ad that encourages people with HIV to “keep being you.”

Published
16 hours ago
From
FiercePharma
Novel Antibody May Suppress HIV for Up to Four Months

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine.

Published
17 hours ago
From
NIAID
Hivpoint Helsinki welcomes Pre-Exposure Prophylaxis – Finnish national guidelines are here, and generic medicines hit the market soon

The National Institute for Health and Welfare recommends PrEP for people with a high risk for HIV transmission. As a part of a comprehensive prevention program, PrEP has reduced new HIV transmissions in all countries where it is available. When used correctly, PrEP provides up to 99% reduction in HIV risk. The Finnish national guidelines are released today, 17 April 2019.

Published
17 April 2019
From
Hivpoint
Game Changers in HIV: Judith Currier

Meet Judith Currier, M.D., a physician-researcher who paved the way for better treatment options for women living with HIV.

Published
17 April 2019
From
The Body Pro
Letter to FDA Regarding Application for Descovy as Pre-Exposure Prophylaxis for HIV

TAG and PrEP4All sent this letter to Dr. Debra Birnkrant of the FDA, outlining and expressing our serious concerns about Gilead’s supplemental New Drug Application for Descovy (FTC/TAF) as HIV-1 preexposure prophylaxis (PrEP). There are several specific recommendations in the letter for this approval process, including recomending that the FDA convene a public meeting of the Antiviral Drug Advisory Committee.

Published
17 April 2019
From
Treatment Action Group
Pre-Exposure Prophylaxis for HIV officially launched in Hanoi

Pre-Exposure Prophylaxis (PrEP) service for HIV prevention was officially launched in Hanoi on April 16.

Published
17 April 2019
From
Vietnam+
Hepatic Steatosis Highly Prevalent in Young Adults With Lifelong HIV

One-third of young adults living with HIV since birth or early childhood have hepatic steatosis.

Published
17 April 2019
From
Infectious Disease Advisor
Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

Published
17 April 2019
From
Medicines and Healthcare products Regulatory Agency
← First12345...1694Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.